Free tool
FAERS Monitor: Evdi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220837 or its brand name (Evdi, Trabectedin). Reports on generic versions are filed under their own applications.
Reports
1,205
Serious
1,178
98% of reports
Hospitalization
547
Death reported
261
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- neutropenia159
- anaemia133
- thrombocytopenia132
- disease progression118
- nausea109
- febrile neutropenia107
- drug ineffective93
- vomiting92
- off label use86
- asthenia72
- fatigue66
- pancytopenia64
- pyrexia60
- leukopenia56
- rhabdomyolysis54
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 2 |
| 2010 | 11 |
| 2011 | 32 |
| 2012 | 19 |
| 2013 | 12 |
| 2014 | 14 |
| 2015 | 48 |
| 2016 | 101 |
| 2017 | 91 |
| 2018 | 121 |
| 2019 | 127 |
| 2020 | 94 |
| 2021 | 71 |
| 2022 | 88 |
| 2023 | 100 |
| 2024 | 107 |
| 2025 | 77 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,954 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 107 | 28.2 | 23.5 | 2,784 |
| rhabdomyolysisSignal | 54 | 22.6 | 17.4 | 1,096 |
| thrombocytopeniaSignal | 132 | 20.6 | 17.6 | 2,456 |
| neutropeniaSignal | 159 | 20.4 | 17.7 | 2,935 |
| pancytopeniaSignal | 64 | 20.0 | 15.8 | 1,139 |
| leukopeniaSignal | 56 | 19.6 | 15.1 | 969 |
| disease progressionSignal | 118 | 17.4 | 14.7 | 1,819 |
| anaemiaSignal | 133 | 12.2 | 10.4 | 1,365 |
| vomitingSignal | 92 | 3.4 | 2.8 | 158 |
| astheniaSignal | 72 | 3.3 | 2.7 | 118 |
| pyrexiaSignal | 60 | 3.0 | 2.4 | 81 |
| nauseaSignal | 109 | 2.4 | 2.0 | 91 |
| off label use | 86 | 1.7 | 1.4 | 26 |
| fatigue | 66 | 1.5 | 1.2 | 10 |
| drug ineffective | 93 | 1.2 | 1.0 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.